Widespread use of measurable residual disease in acute myeloid leukemia practice.

ABSTRACT:

Purpose

Measurable residual disease (MRD) has prognostic importance for patients with acute myeloid leukemia (AML). How leukemia providers incorporate MRD into routine practice remains undefined.

Patients and methods

A survey was developed and distributed to a large sample of leukemia physicians. Demographic information was collected along with details concerning MRD practices. A multivariable logistic regression model evaluated provider characteristics predictive of MRD utilization.

Results

268 responses were received (response rate of 41%). 69% of providers reported routine use of MRD in management of AML, most commonly (90%) for its role in guiding therapy; providers who did not use MRD routinely most frequently cited inadequate resources (58%). Providers utilized

SUBMITTER: Epstein-Peterson ZD 

PROVIDER: S-EPMC7029617 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature